“The existing predicament has uncovered some structural weaknesses within the EU’s medicines provide chain and also a higher dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She recommended that supply chain difficulties be resolved within an EU pharmaceut